Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN

Lissy De Ridder, Amit Assa, Jiri Bronsky, Claudio Romano, Richard K. Russell, Nadeem A. Afzal, Almuthe C. Hauer, Daniela Knafelz, Paolo Lionetti, Caterina Strisciuglio, Gábor Veres, Harland Winter, Victorien M. Wolters, Malgorzata Sladek, Arnold G. Vulto, Jorge A. Dias

Research output: Contribution to journalArticlepeer-review

Abstract

TBiologic therapies have changed the outcome of both adult and pediatric patients with Inflammatory Bowel Disease (IBD). In September 2013, the first biosimilar of infliximab was introduced into the pharmaceutical market. In 2015, a first position paper on the use of biosimilars in pediatric IBD was published by the ESPGHAN IBD Porto group. Since then, more data have accumulated for both adults and children demonstrating biosimilars are an effective and safe alternative to the originator. In this updated position statement, we summarize current evidence and provide joint consensus statements regarding the recommended practice of biosimilar use in children with IBD.

Original languageEnglish
Pages (from-to)144-153
Number of pages10
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume68
Issue number1
DOIs
StatePublished - 2019

Keywords

  • biologics
  • biologics
  • biosimilars
  • biosimilars
  • Crohn disease
  • inflammatory bowel disease
  • pediatric
  • ulcerative colitis

Fingerprint

Dive into the research topics of 'Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN'. Together they form a unique fingerprint.

Cite this